19 Aug 2022 09:13
Spectral MD Holdings, Ltd
("Spectral MD" or the "Company" or the "Group")
Grant of Options
LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it has granted options ("Options") over a total of 1,080,000 common stock of US$0.001 ("Common Stock") in the Company ("Shares") to various new employees of the Company in accordance with the Company's 2018 Long Term Incentive Plan. The Options vest over a three-year period from the date of grant, expire after ten years and have an exercise price of 35.5 pence.
For further information, please contact: | ||||
Spectral MD Holdings, Ltd. | https://investors.spectralmd.com/ | |||
Wensheng Fan, Chief Executive Officer Nils Windler, Chief Financial Officer | via Walbrook PR | |||
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) | +44 (0) 20 3470 0470 | |||
Stuart Gledhill / Caroline Rowe (Corporate Finance) Vadim Alexandre / Rob Rees (Sales and Corporate Broking) | ||||
Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 | |||
Charles Hoare / Ben Maddison / Will Palmer-Brown | ||||
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | |||
Sam Allen / Alice Woodings
| +44 (0)75 0255 8258 / +44 (0) 7407 804654 | |||
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com